Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.
about
Pharmacological Targeting of the Hepcidin/Ferroportin AxisHepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic ReviewLaboratory use of hepcidin in renal transplant recipientsGenomic approaches to identifying targets for treating β hemoglobinopathiesRegulation of Iron Metabolism by Hepcidin under Conditions of InflammationAnemia: progress in molecular mechanisms and therapiesNew advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseasesModulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approachesβ-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapiesIroning out FerroportinIdentification of erythroferrone as an erythroid regulator of iron metabolismIron regulation by hepcidinSuppression of hepcidin expression and iron overload mediate Salmonella susceptibility in ankyrin 1 ENU-induced mutantHepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia.Targeting iron metabolism in drug discovery and deliveryPathophysiological consequences and benefits of HFE mutations: 20 years of research.β-Thalassemia and Polycythemia vera: targeting chronic stress erythropoiesis.Macrophages in multiple myeloma: emerging concepts and therapeutic implications.A chemical screen identifies small molecules that regulate hepcidin expression.Erythroferrone contributes to recovery from anemia of inflammationErythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo.Mouse models of anemia of cancerIron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.Small lipidated anti-obesity compounds derived from neuromedin U.Progesterone receptor membrane component-1 regulates hepcidin biosynthesisReducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemiaModulation of hepcidin to treat iron deregulation: potential clinical applications.Non-transfusion-dependent thalassemias.Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy.Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia veraTesting the iron hypothesis in a mouse model of atherosclerosis.The liver: conductor of systemic iron balance.Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt.The Regulation of Iron Absorption and Homeostasis.Myelodysplastic Syndromes and Iron Chelation TherapyIron metabolism in athletes--achieving a gold standard.The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand?Manipulation of the hepcidin pathway for therapeutic purposes.
P2860
Q26738350-12EA142E-BB76-4A20-AA37-826063E407A7Q26750731-DB492199-2CF7-4AAE-A6A4-CB8037626017Q26765316-4DCDE002-F045-44A1-8DCD-F036A12F2704Q26799214-493BB42A-7E50-44C2-AD30-FDCE0BEE599DQ26852319-75B2D8DF-0C00-4578-BA4E-C158B725896BQ27023172-4CAACCFD-FAB7-4E21-B7E5-B03AD7D2435AQ27026399-4F93CF82-7275-49F2-A53F-11181F21DA76Q27027657-6B6A2909-659D-4FC3-A257-F52FA28588A1Q28086960-612C1411-A7C3-425B-B8A1-914552BEC1B4Q28087429-89302459-362B-40A9-80FC-DF073DC70FDEQ28240988-99F09846-F622-453D-8BBD-1B023BC8E200Q28291718-08E833BA-CEFB-413E-9100-C4C7F9D0AB42Q28505375-2A393141-1954-453B-BC6A-43AF3761F5C5Q30252780-FED5C8FD-CB29-4BB7-AA2D-2A0F73FAB052Q33757232-BA7930B9-E7CC-4D6D-87C7-A91775B9F8CBQ33815961-F83CA63C-4BDA-47A5-9D62-3434EAB532D1Q33853100-2CD283E2-FE04-4A93-8379-27F3D6AAF2AAQ34329242-3C11A8A1-B0C9-442D-9CB4-367578211E45Q34345426-8BBC62CC-A320-432B-A13A-F0E73E290F13Q34353734-2338AD99-5762-4226-B7D2-3764553FC5D1Q34489655-BABA0E46-7290-4535-9128-CBC833104DD0Q34875712-2E140FD8-9531-4334-B6E1-B7169330BE11Q35135015-797EDC73-FC57-4968-9673-76341575864BQ35296244-7A344076-3C56-4DEC-B215-C5BE48F7C063Q35708420-69C396B7-68E3-42EF-B7E7-F35A27DA85BCQ36430759-D32C557C-E8ED-4065-A773-92D2E41F4E52Q36733512-8E4D6A4C-5E24-4F3F-97DB-F3158DC5E1A3Q36745518-C05B1586-F204-4720-AF4F-93F2E4D373FBQ36847852-8D460FC0-BFA2-4063-8520-5321DB28531CQ36892558-BE8664F8-A81C-442E-8531-4B7D7708D1A7Q37060694-D1941C42-D778-4485-A3C4-ADC4331DBA4AQ37097115-F017D5B0-1DDA-439A-AE5F-F0377CF564D3Q37430727-C6F6A6B3-6CA4-4F12-BB5B-7523F1096022Q37464105-3BC547C7-0BC3-4E14-93C2-ED5E2677B2A4Q37538805-18B5214A-0938-4621-8230-545A8C4E9748Q37543492-F7CA822D-4462-4317-98F5-257015F80669Q37677229-681DB897-689C-4A66-8C01-750FD0816D8BQ38053183-F6D22A3E-3E30-4C01-9B17-84084A5CC9E2Q38083570-BF22D071-22AD-46EE-8E75-3511A6687AFEQ38159513-119316FF-F824-40B6-B5F2-DD10370EE5D2
P2860
Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Minihepcidins prevent iron ove ...... del of severe hemochromatosis.
@ast
Minihepcidins prevent iron ove ...... del of severe hemochromatosis.
@en
type
label
Minihepcidins prevent iron ove ...... del of severe hemochromatosis.
@ast
Minihepcidins prevent iron ove ...... del of severe hemochromatosis.
@en
prefLabel
Minihepcidins prevent iron ove ...... del of severe hemochromatosis.
@ast
Minihepcidins prevent iron ove ...... del of severe hemochromatosis.
@en
P2093
P2860
P1433
P1476
Minihepcidins prevent iron ove ...... del of severe hemochromatosis.
@en
P2093
Elizabeta Nemeth
Emilio Ramos
Gloria C Preza
Julia B Goodnough
Piotr Ruchala
P2860
P304
P356
10.1182/BLOOD-2012-07-440743
P407
P577
2012-09-18T00:00:00Z